当前位置: 网站首页 >> 学科方向 >> 临床药理学 >> 正文

陈汇教授课题组

发布者: [发表时间]:2018-06-09 [来源]: [浏览次数]:

主要研究方向:

临床药理学;药物代谢与药物动力学;肿瘤耐药机制;新药研究与评价

主要研究工作:

在中药有效成分对药物代谢酶及转运体表达的调控及其代谢相互作用方面有较深入探讨,并专注于药动学-药效学建模及其在抗肿瘤药物多靶点效应中的研究,以及对肿瘤耐药机制等研究。并完成多项新药临床前及临床药代动力学研究和人体生物等效性评价。

主要期刊论文

1.Zhu YS, Hu J, He WJ, Gao XJ,Hui Chen*. DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A. Chemico-Biological Interactions. 2016, 5(247):55-63

2.Zhu YS, He WJ, Gao XJ, Li B, Mei CH, Xu R,Chen H*. Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Scientific Reports. 2015, 4(12):17730.

3.Mei CH, Li B, Yin QF, Jin J, Xiong T, He WJ, Gao XJ, Xu R, Zhou PQ, Zheng H,Chen H*. Liquid chromatography-tandem mass spectrometry for the quantification of flurbiprofen in human plasma and its application in a study of bioequivalence. Journal of Chromatography B. 2015,5(5):993:69-74.

4.Hui Chen, Xinxia Liu, Heng Wan, Can Zeng. The Pharmacokinetics /Pharmacodynamics of resveratrol and mechanism-based PK-PD modeling research. The FASEB Journal.2014,28(suppl.)

5.Aimei Gao, Zunping Ke, Jianing Wang,Jianye Yang, Shiyou chen,Hui Chen*.Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 2013;34:1806-1814

6.Aimei Gao, Zunping Ke, Fang Shi,Hui Chen*. Chrysin enhances sensitivity of BEL-7402/ADM cell to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chemico-Biological Interactions. 2013;206:100-108

7.Guanghui Huang, Jianping Wan,Hui Chen*.Density-based Monte Carlo filter and its applications in nonlinear stochastic differential equation models. Computers in Biology and Medicine. 2013;43:135-143

8.Xinxia Liu, Heng Zheng, Wei Tang, Zhenyu Qian, Yinsong Zhu,Jing Wang,Shiying Yuan, Xin Wen,Cuiing Cao,Hui Chen*.Development of a novel LC–MS/MS method for the determination of letosteine in human plasma and its application on pharmacokinetic studies.J Chromatogr B.2011;879(25):2554-2560

9.Wei Tang,Xinxia Liu, Xiangjun Qiu, Shiying Yuan, Jing Wan,Hui Chen*.A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers.Arzneimittelforschung.2011;61(7):411-416

10.Libo Zhao, Shifen Gu, Rong Xu, Xiaoyu Cui, Fangliang Gan,Hui Chen*.Comparison ofliquid chromatography-ultraviolet and chromatography-tandem mass spectrometry for the determination of indapamide in human whole blood and their applications in bioequivalence studies.Arzneimittelforschung.2010;60(7):432-439

11.Libo Zhao, Xiaoyan Yang, Rong Xu, Jianhong Wu, Shifen Gu, Li Zhang, Peili Gong,Hui Chen*,Fandian Zeng. Safety, tolerability and pharmacokinetics of phenoprolamine hydrochloride floating sustained-release tablets in healthy Chinese subjects. International Journal of Pharmaceutics.2009:377: 99–104

12.Zhao Li-bo, Hu Jiong, Chang Qing, Ke Qiu-lin, Xu Rong, Gu Shi-fen,Chen Hui*and Zeng Fan-dian. A simple and sensitive HPLC method for quantitation of low phenoprolamine hydrochloride concentrations in human plasma and its pharmacokinetic application. Biomed Chromatogr. 2008; 22(3):333

主要科研项目:

1.国家自然科学基金:随机环境下的药动学-药效学建模及其在白藜芦醇抗肿瘤多靶点效应中的研究

2.国家高技术研究发展计划子课题:一类抗高血压新药盐酸非洛普的研究“盐酸非洛普缓释制剂一期临床试验”

3.国家高技术研究发展计划子课题:纳米生物磁靶向载药微球治疗肝胆胰恶性肿瘤的研究

4.湖北省自然科学基金:中药对实验性动脉再狭窄保护作用机制研究

5.湖北省重点科技发展计划:蝙蝠葛碱类药代动力学与药效动力学相关性研究

6.华中科技大学科研基金:基于rhCYP3A4抑制作用的黄酮类化合物体外药代筛选3D-QSAR模型的建立

7.新药临床研究:抗高血压一类新药盐酸非洛普缓释制剂临床耐受性及药代动力学研究;抗肺纤维化一类新药吡非尼酮临床药代动力学研究;比索洛尔氢氯噻嗪片临床药代动力学(桥接试验);氟比洛芬酯注射液人体生物等效性试验等

发明专利:

专利名称:咖伦宾在制备治疗2型糖尿病药物中的应用

授权时间:2012年07月04日

专利号:ZL 2009 1 0273174.4